- Home
- ELLO vs ABOS Comparison
ELLO vs ABOS Comparison
Compare ELLO & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELLO
- ABOS
- Stock Information
- Founded
- ELLO 1987
- ABOS 1996
- Country
- ELLO Israel
- ABOS United States
- Employees
- ELLO N/A
- ABOS N/A
- Industry
- ELLO Electric Utilities: Central
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- ELLO Utilities
- ABOS Health Care
- Exchange
- ELLO Nasdaq
- ABOS Nasdaq
- Market Cap
- ELLO 181.0M
- ABOS 171.8M
- IPO Year
- ELLO 1995
- ABOS 2021
- Fundamental
- Price
- ELLO $14.72
- ABOS $2.24
- Analyst Decision
- ELLO
- ABOS Strong Buy
- Analyst Count
- ELLO 0
- ABOS 4
- Target Price
- ELLO N/A
- ABOS $9.00
- AVG Volume (30 Days)
- ELLO 3.5K
- ABOS 207.8K
- Earning Date
- ELLO 12-31-2024
- ABOS 11-12-2024
- Dividend Yield
- ELLO N/A
- ABOS N/A
- EPS Growth
- ELLO N/A
- ABOS N/A
- EPS
- ELLO N/A
- ABOS N/A
- Revenue
- ELLO $46,384,871.00
- ABOS N/A
- Revenue This Year
- ELLO N/A
- ABOS N/A
- Revenue Next Year
- ELLO N/A
- ABOS N/A
- P/E Ratio
- ELLO N/A
- ABOS N/A
- Revenue Growth
- ELLO N/A
- ABOS N/A
- 52 Week Low
- ELLO $11.08
- ABOS $2.08
- 52 Week High
- ELLO $20.26
- ABOS $5.09
- Technical
- Relative Strength Index (RSI)
- ELLO 65.24
- ABOS 35.46
- Support Level
- ELLO $13.19
- ABOS $2.85
- Resistance Level
- ELLO $14.58
- ABOS $3.36
- Average True Range (ATR)
- ELLO 0.51
- ABOS 0.25
- MACD
- ELLO 0.04
- ABOS -0.10
- Stochastic Oscillator
- ELLO 91.28
- ABOS 0.00
About ELLO Ellomay Capital Ltd (Israel)
Ellomay Capital Ltd is focused on the utility sector. It is an Israeli public company, which focuses its business in the energy and infrastructure sectors. The company's operating segment includes Photovoltaic power plants (PV Plants); Dorad Energy Ltd. (Dorad); Groen Gas Goor B.V. and a Pumped storage hydro power plant (Manara). It generates maximum revenue from the Dorad segment. Geographically, it derives a majority of its revenue from Spain.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.